Immunomodulatory News and Research

RSS
Novartis presents positive Phase III results of Farydak therapy at EHA

Novartis presents positive Phase III results of Farydak therapy at EHA

Janssen begins rolling submission of daratumumab BLA to FDA for treatment of patients with multiple myeloma

Janssen begins rolling submission of daratumumab BLA to FDA for treatment of patients with multiple myeloma

Elotuzumab boosts response in relapsed, refractory multiple myeloma

Elotuzumab boosts response in relapsed, refractory multiple myeloma

MorphoSys' MOR202 proprietary drug candidate meets primary endpoints in multiple myeloma patients

MorphoSys' MOR202 proprietary drug candidate meets primary endpoints in multiple myeloma patients

ASCO 2015: AMGEN presents new data evaluating less-frequent dosing of kyprolis for multiple myeloma patients

ASCO 2015: AMGEN presents new data evaluating less-frequent dosing of kyprolis for multiple myeloma patients

ASCO 2015: AMGEN presents new data evaluating less-frequent dosing of kyprolis for multiple myeloma patients

ASCO 2015: AMGEN presents new data evaluating less-frequent dosing of kyprolis for multiple myeloma patients

Amgen starts Phase 3 study assessing the benefit of Kyprolis in patients with relapsed/refractory multiple myeloma

Amgen starts Phase 3 study assessing the benefit of Kyprolis in patients with relapsed/refractory multiple myeloma

Daratumumab achieves 29.2% overall response rate in heavily pre-treated patients with multiple myeloma

Daratumumab achieves 29.2% overall response rate in heavily pre-treated patients with multiple myeloma

Brain Tumor Biotech Summit held in Manhattan on 29 May, 2015

Brain Tumor Biotech Summit held in Manhattan on 29 May, 2015

Monoclonal antibody nivolumab improves survival rates of melanoma patients

Monoclonal antibody nivolumab improves survival rates of melanoma patients

BioNTech, Genmab to jointly develop and commercialize immunomodulatory antibodies for cancer

BioNTech, Genmab to jointly develop and commercialize immunomodulatory antibodies for cancer

Canada-US researchers to jointly study effectiveness of AIO treatment in patients with late stage cancer

Canada-US researchers to jointly study effectiveness of AIO treatment in patients with late stage cancer

Amgen receives FDA priority review designation for Kyprolis to treat relapsed multiple myeloma

Amgen receives FDA priority review designation for Kyprolis to treat relapsed multiple myeloma

Co-infection reduces severity of East Coast fever, can help curb human malaria

Co-infection reduces severity of East Coast fever, can help curb human malaria

Researchers turn clinical experience in multiple myeloma treatment into instructive review for physicians

Researchers turn clinical experience in multiple myeloma treatment into instructive review for physicians

Isis Pharmaceuticals, AstraZeneca partner to develop new delivery methods for antisense oligonucleotides

Isis Pharmaceuticals, AstraZeneca partner to develop new delivery methods for antisense oligonucleotides

Inovio Pharmaceuticals reports Q3 2014 financial results, provides corporate update

Inovio Pharmaceuticals reports Q3 2014 financial results, provides corporate update

Alzheimer's disease report success in harnessing mouse's immune system to attack toxic proteins

Alzheimer's disease report success in harnessing mouse's immune system to attack toxic proteins

Experts examine how molecule in parasitic worms can effectively treat autoimmune diseases

Experts examine how molecule in parasitic worms can effectively treat autoimmune diseases

Inovio Pharmaceuticals reports increased revenue in second quarter 2014

Inovio Pharmaceuticals reports increased revenue in second quarter 2014

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.